

Appendix 1 (as supplied by the authors): Oral systemic therapy drugs

abiraterone	etoposide	nilotinib
acitretin	everolimus	nilutamide
anagrelide	exemestane	pazopanib
anastrozole	fludarabine	prednisolone
bicalutamide	flutamide	prednisone
bromocriptine	gefitinib	procarbazine
busulfan	hydroxyurea	quinagolide
cabergoline	imatinib	ruxolitinib
capecitabine	isotretinoin	sorafenib
chlorambucil	lapatinib	sunitinib
clodronate	lenalidomide	tamoxifen
crizotinib	letrozole	temozolomide
cyclophosphamide	lomustine	thalidomide
cyclosporine	medroxyprogesterone	thioguanine
cyproterone	megestrol	tretinoin
dasatinib	melphalan	vemurafenib
enzalutamide	mercaptopurine	vismodegib
erlotinib	methotrexate	
estramustine	mitotane	